Oculis Holding AG (OCS)
NASDAQ: OCSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
OCS stock chart
Technical analysisKey statistics
All statistics- Market cap
- $393.35M
- EPS (TTM)
- -$1.69
- Dividend yield
- None
- 52-week range
- 6.78 – 34.48
- Day range
- 6.99 – 7.43
- Volume / Avg
- 235.18K / 272.83K
- Beta
- —
- Shares outstanding
- 55.72M
52-week range
OCS stock today
On Nov 20, OCS ended the session at $7.06, shedding $0.38 (5.11%), versus the S&P 500's 3.70% decline. Shares are 79.5% below their 52-week high of $34.48, set on May 11, 2026 and 4.1% above the 52-week low of $6.78, near the bottom of the past year's range. OCS is down 64.6% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 63.3%.
Oculis has posted a net loss over the last twelve months (EPS of -$1.69), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Oculis
Company profileOculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. Oculis Holding AG was formerly known as Oculis SA and changed its name to Oculis Holding AG in March 2023.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Riad Sherif M.B.A., M.D.
- Headquarters
- Zug
- Employees
- 60
- Website
- oculis.com
Analyst forecast
ForecastConsensus (10 analysts)
strong_buy
Avg. price target
$35.85+407.79%
- Strong buy 3
- Buy 7
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 3, 2026
- EPS actual vs est.
- $-0.37 vs $-0.49
- Surprise
- +24.49%
OCS news
All OCS news- Oculis Gets FDA Clearance To Advance Privosegtor In Acute Multiple Sclerosis RelapsesNasdaqOCS, HEI.A
- Oculis Announces FDA IND Clearance Enabling Acceleration of Privosegtor Development Program in Acute Multiple Sclerosis RelapsesGlobeNewswire
- Oculis tilkynnir að FDA hafi samþykkt IND-umsókn (e. Investigational New Drug application) sem gerir félaginu kleift að hraða þróunaráætlun Privosegtor við bráðum köstum MS-sjúkdómsGlobeNewswire
- Oculis Announces FDA IND Clearance Enabling Acceleration of Privosegtor Development Program in Acute Multiple Sclerosis RelapsesGlobeNewswire
- Oculis Publishes Notifications of Transactions by Persons Discharging Managerial ResponsibilitiesGlobeNewswire
- Oculis Holding AG: Samningur um viðskiptavakt við Fossa fjárfestingarbanka hf.GlobeNewswire
- Oculis to Host In-Person and Virtual R&D Day: Advancing a Differentiated Late-Stage Development PipelineGlobeNewswire
- Oculis boðar til rannsóknar- og þróunardags (e. R&D Day) bæði í streymi og á staðnum: Framþróun þróunarlyfja með skýra sérstöðu á síðari stigum klínískrar þróunarGlobeNewswire
Oculis peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| AVTXAvalo Therapeutics Inc. | 6.76 | +0.15% | $390.88M | vs OCS |
| IRDOpus Genetics Inc. | 3.99 | -2.21% | $385.65M | vs OCS |
| PHATPhathom Pharmaceuticals Inc. | 4.66 | -8.27% | $378.82M | vs OCS |
| OVIDOvid Therapeutics Inc. | 2.20 | -5.98% | $415.21M | vs OCS |
| CRMDCorMedix Inc. | 5.27 | +3.74% | $419.16M | vs OCS |
| PRTAProthena Corporation plc | 8.22 | -2.14% | $422.10M | vs OCS |
| PBYIPuma Biotechnology Inc | 7.05 | -0.98% | $364.47M | vs OCS |
| ARVNArvinas Inc. | 6.46 | -4.15% | $423.03M | vs OCS |
Indexes, lists and sector
Oculis stock FAQ
What is Oculis's stock price today?
OCS last traded at $7.06 as of Nov 20, 4:00 PM EST, down 5.11% on the day. Prices are delayed at least 15 minutes.
Who is Oculis's CEO?
Dr. Riad Sherif M.B.A., M.D. is the chief executive officer of Oculis Holding AG, which has about 60 employees.
What is the OCS 52-week high?
The 52-week high for OCS is $34.48 and the 52-week low is $6.78. The stock is currently 79.5% below its high.